IGFBPs mediate IGF-1's functions in retinal lamination and photoreceptor development during pluripotent stem cell differentiation to retinal organoids. 2021

Darin Zerti, and Marina Moya Molina, and Birthe Dorgau, and Sarah Mearns, and Roman Bauer, and Jumana Al-Aama, and Majlinda Lako
Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Development of the retina is regulated by growth factors, such as insulin-like growth factors 1 and 2 (IGF-1/2), which coordinate proliferation, differentiation, and maturation of the neuroepithelial precursors cells. In the circulation, IGF-1/2 are transported by the insulin growth factor binding proteins (IGFBPs) family members. IGFBPs can impact positively and negatively on IGF-1, by making it available or sequestering IGF-1 to or from its receptor. In this study, we investigated the expression of IGFBPs and their role in the generation of human retinal organoids from human pluripotent stem cells, showing a dynamic expression pattern suggestive of different IGFBPs being used in a stage-specific manner to mediate IGF-1 functions. Our data show that IGF-1 addition to culture media facilitated the generation of retinal organoids displaying the typical laminated structure and photoreceptor maturation. The organoids cultured in the absence of IGF-1, lacked the typical laminated structure at the early stages of differentiation and contained significantly less photoreceptors and more retinal ganglion cells at the later stages of differentiation, confirming the positive effects of IGF-1 on retinal lamination and photoreceptor development. The organoids cultured with the IGFBP inhibitor (NBI-31772) and IGF-1 showed lack of retinal lamination at the early stages of differentiation, an increased propensity to generate horizontal cells at mid-stages of differentiation and reduced photoreceptor development at the later stages of differentiation. Together these data suggest that IGFBPs enable IGF-1's role in retinal lamination and photoreceptor development in a stage-specific manner.

UI MeSH Term Description Entries
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D007335 Insulin-Like Growth Factor II A well-characterized neutral peptide believed to be secreted by the LIVER and to circulate in the BLOOD. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on SOMATOTROPIN. It is believed to be a major fetal growth factor in contrast to INSULIN-LIKE GROWTH FACTOR I, which is a major growth factor in adults. IGF-II,Multiplication-Stimulating Activity,Somatomedin MSA,IGF-2,Insulin Like Growth Factor II,Insulin-Like Somatomedin Peptide II,Multiplication-Stimulating Factor,Somatomedin A,Factor, Multiplication-Stimulating,Insulin Like Somatomedin Peptide II,Multiplication Stimulating Activity,Multiplication Stimulating Factor
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009940 Organoids An organization of cells into an organ-like structure. Organoids can be generated in culture, e.g., self-organized three-dimensional tissue structures derived from STEM CELLS (see MICROPHYSIOLOGICAL SYSTEMS). They are also found in certain NEOPLASMS. Organoid
D002396 Catechols A group of 1,2-benzenediols that contain the general formula R-C6H5O2. Pyrocatechols,o-Dihydroxybenzenes,ortho-Dihydroxybenzenes,o Dihydroxybenzenes,ortho Dihydroxybenzenes
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000067778 ELAV-Like Protein 3 A neural-specific RRM protein which contains three RNP-type RNA recognition motifs (RRMs). Human ELAVL3 is recognized by the anti-Hu serum antibody from patients with paraneoplastic encephalomyelitis and sensory neuronopathy (PEM/PSN). It also functions in neurogenesis. ELAVL3 Protein,HuC Antigen,HuC Paraneoplastic Encephalomyelitis Antigen,HuC Protein,3, ELAV-Like Protein,Antigen, HuC,ELAV Like Protein 3,Protein 3, ELAV-Like,Protein, ELAVL3,Protein, HuC

Related Publications

Darin Zerti, and Marina Moya Molina, and Birthe Dorgau, and Sarah Mearns, and Roman Bauer, and Jumana Al-Aama, and Majlinda Lako
February 2022, Cell death discovery,
Darin Zerti, and Marina Moya Molina, and Birthe Dorgau, and Sarah Mearns, and Roman Bauer, and Jumana Al-Aama, and Majlinda Lako
April 2022, Stem cell reports,
Darin Zerti, and Marina Moya Molina, and Birthe Dorgau, and Sarah Mearns, and Roman Bauer, and Jumana Al-Aama, and Majlinda Lako
January 2016, Molecular vision,
Darin Zerti, and Marina Moya Molina, and Birthe Dorgau, and Sarah Mearns, and Roman Bauer, and Jumana Al-Aama, and Majlinda Lako
September 2019, Current protocols in stem cell biology,
Darin Zerti, and Marina Moya Molina, and Birthe Dorgau, and Sarah Mearns, and Roman Bauer, and Jumana Al-Aama, and Majlinda Lako
January 2020, Methods in cell biology,
Darin Zerti, and Marina Moya Molina, and Birthe Dorgau, and Sarah Mearns, and Roman Bauer, and Jumana Al-Aama, and Majlinda Lako
July 2021, Stem cells (Dayton, Ohio),
Darin Zerti, and Marina Moya Molina, and Birthe Dorgau, and Sarah Mearns, and Roman Bauer, and Jumana Al-Aama, and Majlinda Lako
October 2020, Stem cells (Dayton, Ohio),
Darin Zerti, and Marina Moya Molina, and Birthe Dorgau, and Sarah Mearns, and Roman Bauer, and Jumana Al-Aama, and Majlinda Lako
April 2022, Stem cells translational medicine,
Darin Zerti, and Marina Moya Molina, and Birthe Dorgau, and Sarah Mearns, and Roman Bauer, and Jumana Al-Aama, and Majlinda Lako
May 2018, Cell death & disease,
Darin Zerti, and Marina Moya Molina, and Birthe Dorgau, and Sarah Mearns, and Roman Bauer, and Jumana Al-Aama, and Majlinda Lako
August 2020, Stem cell research & therapy,
Copied contents to your clipboard!